FTC sues Amgen to block Horizon takeover

2023-05-17

并购高管变更

The Federal Trade Commission is seeking to block Amgen from acquiring Horizon Therapeutics, claiming the mega-deal would allow Amgen to leverage its blockbuster portfolio to gain monopoly positions on Horizon medications.

The FTC filed a lawsuit in federal court to block the proposed $27.8 billion transaction, saying the deal would allow Amgen to use rebates on its existing blockbuster drugs to pressure insurance companies and pharmacy benefit managers into favoring Horizon’s two key drugs — Tepezza and Krystexxa — neither of which have market competition.

A hint at what was coming came in February, when Horizon and Amgen revealed that they had received a request from the FTC for additional information and documentary materials concerning the proposed acquisition.

The acquisition, announced in December 2022, will give Amgen access to Horizon’s lead thyroid eye disease drug, Tepezza, and Krystexxa, used to treat chronic refractory gout.

The proposed acquisition was the largest pharma transaction announced in 2022.

Concerned about the increased consolidation in the biopharma space, back in 2021 the FTC announced a new working group, comprised of antitrust enforcers from around the globe, focused on taking “an aggressive approach to tackling anticompetitive pharmaceutical mergers.” The initiative vowed to more closely evaluate pharma mergers in light of concerns about anticompetitive behavior and drug pricing.

Back in April, Sanofi had to withdraw and refile its pre-merger notification and report form in connection with its pending $2.9 billion acquisition of Provention Bio in order to provide the FTC with additional time for a closer review.

“Rampant consolidation in the pharmaceutical industry has given powerful companies a pass to exorbitantly hike prescription drug prices, deny patients access to more affordable generics, and hamstring innovation in life-saving markets,” said FTC Bureau of Competition director Holly Vedova in a press release about the Amgen lawsuit. “Today’s action — the FTC’s first challenge to a pharmaceutical merger in recent memory — sends a clear signal to the market: The FTC won't hesitate to challenge mergers that enable pharmaceutical conglomerates to entrench their monopolies at the expense of consumers and fair competition.”

Karen currently serves as Pharma Manufacturing's chief content director.

Formerly the editor-in-chief of Food Manufacturing magazine, Karen was particularly successful at eating all of the snacks that were mailed to her from food companies, as well as reaching readers by establishing her own unique voice and tone on the brand. She made the decision to trade food for drugs in 2013, when she joined Putman Media as the digital content manager for Pharma Manufacturing.

As an award-winning journalist with 20+ years experience in the B2B manufacturing space, Karen passionately believes that B2B content does not have to suck. As the content director, her ongoing mission has been to keep Pharma Manufacturing's editorial look, tone and editorials fresh and accessible.

Karen graduated with honors from Bucknell University, where she played Division 1 softball and occasionally did some schoolwork. Happily living in NJ's famed Asbury Park, Karen is a retired Garden State Rollergirl, known to the roller derby community as the 'Predator-in-Chief.'

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构